Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7252186 | 0.90 | TSHR (0.69) | TSHRSMN1; SMN2ALDH1A1PKMHDAC3 | |
| SCHEMBL3598004 | 0.82 | TSHR (0.61) | TSHRSMN1; SMN2ALDH1A1PKMHDAC3 | |
| SCHEMBL10117993 | 0.82 | TSHR (0.61) | TSHRSMN1; SMN2ALDH1A1PKMNPC1 | |
| SCHEMBL3598006 | 0.82 | TSHR (0.61) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL2721206 | 0.81 | ALDH1A1 (0.65) | TSHRSMN1; SMN2ALDH1A1PKMNPC1 | |
| Hydrochloric Acid SCHEMBL29094269 | 0.81 | TSHR (0.59) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL2755804 | 0.81 | TSHR (0.59) | TSHRSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL3006709 | 0.81 | TSHR (0.59) | TSHRSMN1; SMN2ALDH1A1HDAC3HDAC1 | |
| SCHEMBL19321442 | 0.81 | TSHR (0.59) | TSHRSMN1; SMN2ALDH1A1RAB9AKMT2A | |
| SCHEMBL1720194 | 0.80 | ALDH1A1 (0.67) | TSHRSMN1; SMN2ALDH1A1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754743-B2 | Heteroarylcarbamoylbenzene derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | MSD K.K. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-7432287-B2 | Heteroarylcarbamoylbenzene derivative | BANYU PHARMECEUTICAL CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | MSD K.K. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1600442-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | GCK, GCKR, KHK | TSHR 2079/4885SMN1; SMN2 4432/4885ALDH1A1 707/4885 |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | GCK, GCKR, GALK1 | TSHR 3647/4885SMN1; SMN2 4329/4885ALDH1A1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.